The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial - Nature Medicine In this phase 2, randomized trial in early Alzheimer’s disease, the TREM2 agonistic antibody AL002 showed target engagement but did not meet the primary endpoint of change from baseline in Clinical De...

Results from the #INVOKE2 phase 2 trial of the #TREM2 agonistic #antibody #AL002 in early #Alzheimers disease out now. Although #AL002 showed target engagement, no change in CDR-SB was seen. #microglia #dementia #AD
www.nature.com/articles/s41...